Literature DB >> 411644

Treatment of herpetic keratitis.

J Blake, M Browne.   

Abstract

Idoxuridine which was first used in 1960 (Kaufman et al., 1962), has been for many years the only antiviral agent available in the treatment of herpetic keratitis. It is however no more successful than is mechanical removal of diseased epithelium (Patterson & Jones, 1967), and furthermore it may give rise to serious toxic side effects. The search for an alternative medication is therefore a pressing one. Trifluorothymidine (F3T) has, in recent years, been shown to be more effective than IDU and to be free from significant toxicity. Both of these drugs are pyrimidine nucleosides. Adenine Arabinoside or Arabinoside-A (Ara-A) is, by contrast, a purine nucleoside. It is thought to exert its antiviral effect by blocking DNA polymerase and ribonucleotide reductase.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 411644     DOI: 10.1007/bf00171452

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  2 in total

1.  The management of ocular herpes.

Authors:  A Patterson; B R Jones
Journal:  Trans Ophthalmol Soc U K       Date:  1967

2.  Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex keratitis.

Authors:  H KAUFMAN; E L MARTOLA; C DOHLMAN
Journal:  Arch Ophthalmol       Date:  1962-08
  2 in total
  4 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

2.  The treatment of herpes simplex virus epithelial keratitis.

Authors:  K R Wilhelmus
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 3.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

4.  Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.

Authors:  L M Collum; A Benedict-Smith; I B Hillary
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.